We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
-9.57%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$121M
AUM Growth
-$2.42M
Cap. Flow
+$13.3M
Cap. Flow %
10.95%
Top 10 Hldgs %
67.92%
Holding
31
New
5
Increased
12
Reduced
6
Closed
6

Top Buys

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$3.46M
2
CERN
Cerner Corp
CERN
+$3.45M
3
EVH icon
Evolent Health
EVH
+$3.35M
4
FMI
Foundation Medicine, Inc.
FMI
+$2.82M
5
AMRS
Amyris Inc.
AMRS
+$2.8M

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$3.97M
2
EXAS
Exact Sciences
EXAS
+$2.88M
3
GHDX
Genomic Health, Inc.
GHDX
+$2.6M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$2.2M
5
IBB icon
iShares Biotechnology ETF
IBB
+$1.45M

Sector Composition

Rank Sector Weight
1 Healthcare 81.46%
2 Materials 2.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXAS
26
DELISTED
Exact Sciences
EXAS
– –
-155,000
Closed -$2.88M
IBB icon
27
iShares Biotechnology ETF
IBB
$9.21B
– –
-15,000
Closed -$1.45M
IONS icon
28
Ionis Pharmaceuticals
IONS
$9.06B
– –
-33,000
Closed -$1.21M
CLVS
29
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-110,000
Closed -$3.97M
GHDX
30
DELISTED
Genomic Health, Inc.
GHDX
– –
-90,000
Closed -$2.6M
RXDX
31
DELISTED
Ignyta, Inc.
RXDX
– –
-195,000
Closed -$1.23M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q4 2016 Portfolio in Review

As of Q4 2016, Casdin Capital held 31 positions worth $121M, down 2% from $123M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Casdin Capital deployed $13.3M of net new capital in Q4 2016, opening 5 new positions and adding to 12 existing holdings. Its largest new stake was Illumina: 25,700 shares worth $3.2M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 82% a quarter earlier, followed by Materials.

On the sell side, the largest reduction was Agios Pharmaceuticals, an estimated $2.2M trimmed.

  • Casdin Capital's largest Q4 2016 buy was Illumina: 25,700 shares worth $3.2M.
  • Casdin Capital added most to Evolent Health in Q4 2016, an estimated $3.35M increase.
  • Casdin Capital's biggest Q4 2016 reduction was Agios Pharmaceuticals, cutting an estimated $2.2M.
  • Casdin Capital fully exited Clovis Oncology, Inc. in Q4 2016, selling an estimated $3.97M.
  • Casdin Capital's ten largest holdings make up 68% of its $121M portfolio in Q4 2016.
  • Casdin Capital opened 5 new positions and closed 6 in Q4 2016.
  • Casdin Capital's portfolio value fell 2% quarter-over-quarter to $121M.

Based on Casdin Capital's 13F filing for Q4 2016, filed 14 Feb 2017.